Uncategorized-EN
Every patient matters: Building the future of synovial sarcoma research
This year’s winner of the first prize of SPAGN’s Advocacy in Action Awards is the Synovial Sarcoma Foundation based in the US. With a mission to advance research into this rare and aggressive cancer, they established a biorepository and registry to gather patient data. Synovial sarcoma patients worldwide can participate in this game-changing program. Julie Kramer, a synovial sarcoma survivor herself, gives us the background.
Read MoreStrateGIST Frontline
 StrateGIST Frontline: Velzatinib (IDRX-42) vs. Imatinib in patients with metastatic or unresectable GIST, as first-line treatment. Agent: Velzatinib (IDRX-42) Imatinib Phase III Status Recruiting Sponsor GlaxoSmithKline For further information please consult https://clinicaltrials.gov/study/NCT07585266 The purpose of this study is to find out if a new drug, Velzatinib (also known as IDRX-42 or GSK6042981), is effective…
Read MoreAPROMISS
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) Agent: Anlotinib (AL3818) (other name: Catequentinib) Phase III Status Recruiting Sponsor Advenchen Laboratories, LLC For further information please also consult https://clinicaltrials.gov/study/NCT03016819 This study evaluates the safety and efficacy of Anlotinib (AL3818) hydrochloride in the treatment of metastatic or advanced…
Read MoreTEADES
A Phase 1/​2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours (e.g. EHE, Epithelioid hemangioendothelioma) (TEADES) Agent: ODM-212 Phase I/II Status Recruiting Sponsor Orion Corporation, Orion Pharma For further information please also consult https://clinicaltrials.gov/study/NCT06725758. This is a multi-center, open-label, first-in-human study with 2 parts in subjects with selected advanced solid tumours…
Read MoreFrom listening to action: Patients’ voices are shaping sarcoma care in Italy
Concrete improvements in sarcoma care in Italy are becoming a reality. The country’s first Sarcoma White Paper maps out 14 recommendations based on patients’ priorities, and its implementation has already begun. The Fondazione Paola Gonzato-Rete Sarcoma ETS, founded by Ornella Gonzato, was honored for this landmark initiative last May by SPAGN with an Advocacy in Action Award. Martina Gherlinzoni, a member of the Foundation’s Board of Directors, explains what makes their project so distinctive that it has become a major national news story in Italy.
Read MoreASCO 2026: Strong Momentum for Sarcoma Research
By Kathrin Schuster & Bernd Kasper, June 2026 ASCO 2026 was a remarkable year for sarcoma research: The program included several phase III trials, new targeted therapies, cell therapy approaches, translational research, and biomarker-driven strategies, reflecting the continued evolution of the field. Compared with previous years, sarcoma had a particularly visible presence at this year’s…
Read MoreSTC-15
STC-15 in Combination With Toripalimab in Selected Advanced Cancers and as Monotherapy in Selected Sarcomas Agent: STC-15 (a METTL3 inhibitor) Phase Ib/II Status Recruiting Sponsor STORM Therapeutics LTD For further information please also consult https://clinicaltrials.gov/study/NCT06975293 This is an open-label, non-randomized, multi-cohort, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of STC-15 (a…
Read MoreSPAGN Annual Conference 2026 Highlights ✨
Photos: Uli Deck A Global Community United by Hope and Collaboration The SPAGN Annual Conference 2026, held in Stockholm, Sweden at Karolinska University Hospital and Elite Hotel Carolina Tower, once again demonstrated the strength, warmth, and determination of the global sarcoma community. Bringing together patients, advocates, healthcare professionals, researchers, and industry partners from around the…
Read MoreBy bike from Berlin to the Taj Mahal: Young Ewing sarcoma survivor starts charity tour
At the age of 22, John MĂĽller was diagnosed with an Ewing sarcoma, followed by ten months of multimodal therapy. Three years later, he plans to set off by bicycle from Germany to India. His goal: to raise awareness of Ewing sarcomas and to mobilize donations for an emergency fund for sarcoma patients, particularly adolescents and young adults (AYA). Shortly before the start of his journey, John spoke with Voices of Sarcoma.
Read MoreUSA: Rutledge Cancer Foundation
USA: Rutledge Cancer Foundation Back to members Organisation Profile Patient Support and Resources They fund programs and provide resources to meet the emotional and physical needs of AYA patients with cancer — offering support where it’s needed most. About the Research They Fund They focus on funding research and clinical trials…
Read More